Positron emission tomography with (18F)methylspiperone demonstrates D2 dopamine receptor binding differences of clozapine and haloperidol.
Four schizophrenic patients were investigated with dynamic positron emission tomography (PET) using (18F)fluorodeoxyglucose (FDG) and (18F)methylspiperone (MSP) as tracers. Two schizophrenics were on haloperidol therapy at the time of MSP PET. The other two schizophrenics were treated with clozapine, in one of them MSP PET was carried out twice with different daily doses (100 mg and 450 mg respectively). Neuroleptic serum levels were measured in all patients. Results were compared with MSP PET of two drug-free male control subjects and with a previous fluoroethylspiperone (FESP) study of normals. Three hours after tracer injection specific binding of MSP was observed in the striatum in all cases. The striatum to cerebellum ratio was used to estimate the degree of neuroleptic-caused striatal D2 dopamine receptor occupancy. In the haloperidol treated patients MSP binding was significantly decreased, whereas in the clozapine treated patients striatum to cerebellum ratio was normal. Even the increase of clozapine dose in the same patient had no influence on this ratio. Despite the smaller number of patients the study shows for the first time in humans that striatal MSP binding reflects the different D2 dopamine receptor affinities of clozapine and haloperidol.
Karbe
H
H
Universitätsklinik für Neurologie, Köln, Federal Republic of Germany.
Wienhard
K
K
Hamacher
K
K
Huber
M
M
Herholz
K
K
Coenen
H H
HH
Stöcklin
G
G
Lövenich
A
A
Heiss
W D
WD
D000328:Adult; D000368:Aged; D001923:Brain Chemistry; D003024:Clozapine / Q000378:metabolism*; D005260:Female; D005462:Fluorine Radioisotopes; D005947:Glucose / Q000378:metabolism; D006220:Haloperidol / Q000378:metabolism* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011954:Receptors, Dopamine / Q000378:metabolism*; D017448:Receptors, Dopamine D2; D012559:Schizophrenia / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000378:metabolism; D013134:Spiperone / Q000031:analogs & derivatives*; D014055:Tomography, Emission-Computed; D014057:Tomography, X-Ray Computed
D005462:Fluorine Radioisotopes; D011954:Receptors, Dopamine; D017448:Receptors, Dopamine D2; D013134:Spiperone; C039167:3-N-methylspiperone; D005947:Glucose; D003024:Clozapine; D006220:Haloperidol